Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research Article
  • Published:

What makes a drug a primary mood stabilizer?

Molecular Psychiatry volume 7, pages S8–S14 (2002)Cite this article

Abstract

The term ‘mood stabilizer’ has been applied to a number of medications for the treatment of patients with bipolar disorder. The operational definition of the properties of a mood-stabilizing medication has varied according to the properties of specific medications and the clinical characteristics of the illness. Randomized controlled trials of agents accepted or proposed as mood stabilizers are reviewed to marshall the available evidence in support of this claim. In addition, potential pharmacological mechanisms underlying mood-stabilizing effects of established compounds are reviewed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Keck PE Jr, McElroy SL, Arnold LM . Bipolar disorder Med Clin NA 2001 85: 645–661

    Google Scholar 

  2. McElroy SL, Keck PE Jr, Strakowski SM . Mania, psychosis and antipsychotics J Clin Psychiatry 1996 57: 14–26

    PubMed  Google Scholar 

  3. Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode Am J Psychiatry 1998 155: 646–652

    Article  PubMed  Google Scholar 

  4. Strakowski SM, Keck PE Jr, McElroy SL, West SA, Sax KW, Hawkins JM et al. Twelve-month outcome after a first hospitalization for affective psychosis Arch Gen Psychiatry 1998 55: 49–55

    Article  CAS  PubMed  Google Scholar 

  5. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL . The enduring psychosocial consequences of mania and depression Am J Psychiatry 1993 150: 720–727

    Article  CAS  PubMed  Google Scholar 

  6. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD . Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania Am J Psychiatry 1999 156: 1264–1266

    CAS  PubMed  Google Scholar 

  7. Murray CJL, Lopez AD . The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 Harvard University Press: Cambridge, MA 1996

    Google Scholar 

  8. Strakowski SM, McElroy SL, Keck PE Jr, West SA . Suicidality among patients with mixed and manic bipolar disorder Am J Psychiatry 1996 153: 674–676

    Article  CAS  PubMed  Google Scholar 

  9. Dilsaver S, Chen Y-H, Swann AC, Shoaib AM, Krajewski KJ . Suicidality in patients with pure and depressive mania Am J Psychiatry 1994 151: 1312–1315

    Article  CAS  PubMed  Google Scholar 

  10. Keck PE Jr, McElroy SL . Bipolar disorders. In: Nathan PE, Gorman JA (eds). A Guide to Treatments That Work Oxford University Press: New York 1998

    Google Scholar 

  11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision American Psychiatric Press: Washington, DC 2000

  12. Keck PE Jr, McElroy SL, Kmetz G et al. Clinical features of mania in adulthood In: Shulman K, Tohen M, Kutcher S (eds) Mood Disorders Throughout the Life Span John Wiley & Sons, New York 1996 pp 265–279

    Google Scholar 

  13. Goodwin FK, Jamison KR . Manic-Depressive Illness Oxford University Press: New York 1990

    Google Scholar 

  14. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI, Faedda GL, Swann AC . Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania Am J Psychiatry 1992 149: 1633–1644

    Article  CAS  PubMed  Google Scholar 

  15. Sach GS . Treatment-resistant bipolar depression Psychiatry Clin NA 1996 19: 215–236

    Google Scholar 

  16. Pope HG Jr, Lipsinki JF . Diagnosis in schizophrenia andmanic-depressive illness: a reassessment of the specificity of ‘schizophrenic’ symptoms in light of current research Arch Gen Psychiatry 1978 35: 811–828

    Article  PubMed  Google Scholar 

  17. Rothschild AJ . Management of psychotic, treatment-resistant depression Psychiatric Clin NA 1996 19: 237–252

    CAS  Google Scholar 

  18. Hopkins HS, Gelenberg AJ . Treatment of bipolar disorder How far have we come? Psychopharmacol Bull 1994 30: 27–37

    CAS  PubMed  Google Scholar 

  19. Calabrese JR, Rapport DJ . Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder J Clin Psychiatry 1999 60 (Suppl 5): 5–13

    Google Scholar 

  20. Keck PE Jr, McElroy SL . Redefining mood stabilization J Affect Disord 2001 (in press)

  21. Manji HK, Duman RS . Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapies Psychopharmacol Bull 2001 35: 5–49

    CAS  PubMed  Google Scholar 

  22. Manji HK, Drevets WC, Charney DS . The cellular neurobiology of depression Nature Med 2001 7: 541–552

    Article  CAS  PubMed  Google Scholar 

  23. Dunner DL, Fieve RR . Clinical factors in lithium carbonate prophylaxis failure Arch Gen Psychiatry 1974 30: 229–233

    Article  CAS  PubMed  Google Scholar 

  24. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J . Depression during mania: treatment response to lithium or divalproex Arch Gen Psychiatry 1997 54: 37–42

    Article  CAS  PubMed  Google Scholar 

  25. Keck PE Jr, McElroy SL . Treatment of bipolar disorder with lithium Psychiatr Ann 1993 23: 1–6

    Article  Google Scholar 

  26. Keck PE Jr, McElroy SL, Strakowski SM . Anticonvulsants and antipsychotics in the treatment of bipolar disorder J Clin Psychiatry 1998 59 (Suppl 6): 74–82

    Google Scholar 

  27. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study Arch Gen Psychiatry 2000 57: 841–849

    Article  CAS  PubMed  Google Scholar 

  28. Calabrese JR, Delucci GA . Spectrum of efficacy of valproate in 55 patients with rapid cycling bipolar disorder Am J Psychiatry 1990 147: 431–434

    Article  CAS  PubMed  Google Scholar 

  29. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG et al. Olanzapine versus placebo in the treatment of acute mania Am J Psychiatry 1999 156: 702–709

    CAS  PubMed  Google Scholar 

  30. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI . Valproate in the treatment of acute mania. A placebo-controlled study Arch Gen Psychiatry 1991 48: 62–68

    Article  PubMed  Google Scholar 

  31. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F . Efficacy of divalproex vs lithium and placebo in the treatment of mania JAMA 1994 271: 918–924

    Article  CAS  PubMed  Google Scholar 

  32. Tohen M, Zhang F, Feldman P et al. Olanzapine versus haloperidol treatment of acute mania. New Research Program and Abstracts of the American Psychiatric Association Annual Meeting, New Orleans, LA, 2001 p 105

  33. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK . Does olanzapine have antidepressant properties? A retrospective preliminary study Bipolar Disord 2000 2: 196–199

    Article  CAS  PubMed  Google Scholar 

  34. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG et al. A novel augmentation strategy for treating resistant major depression Am J Psychiatry 2001 158: 131–134

    Article  CAS  PubMed  Google Scholar 

  35. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassaf A, Petty F et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder Arch Gen Psychiatry 2000 57: 481–489

    Article  CAS  PubMed  Google Scholar 

  36. McElroy SL, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R et al. Olanzapine in treatment-resistant bipolar disorder J Affect Disord 1998 49: 119–122

    Article  CAS  PubMed  Google Scholar 

  37. Zarate CA Jr, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders J Clin Psychiatry 1998 59: 24–48

    Article  PubMed  Google Scholar 

  38. Keck PE Jr, McElroy SL, Nemeroff CB . Anticonvulsants in the treatment of bipolar disorder J Neuropsychiatry Clin Neurosci 1992 4: 395–405

    Article  PubMed  Google Scholar 

  39. Ballenger JL, Post RM . Therapeutic effects of carbamazepine in affective illness: a preliminary report Commun Psychopharmacol 1978 2: 159–175

    CAS  PubMed  Google Scholar 

  40. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S . Carbamazepine versus lithium in mania: a double-blind study J Clin Psychiatry 1987 48: 89–93

    CAS  PubMed  Google Scholar 

  41. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD et al. Carbamazepine compared with lithium in the treatment of mania Arch Gen Psychiatry 1991 48: 915–921

    Article  CAS  PubMed  Google Scholar 

  42. Grossi E, Sacchetti E, Vita A et al. Carbamazepine verus chlorpromazine in mania; a double-blind trial In: Emrich HM, Okuma T, Muller AA (eds) Anticonvulsants in Affective Disorders Excerpta Medica: Amsterdam, The Netherlands 1984 pp 177–187

    Google Scholar 

  43. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study Psychopharmacology 1979 66: 211–217

    Article  CAS  PubMed  Google Scholar 

  44. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT . Antidepressant effects of carbamazepine Am J Psychiatry 1986 143: 29–34

    Article  CAS  PubMed  Google Scholar 

  45. Small JG . Anticonvulsants in affective disorders Psychopharmacol Bull 1990 26: 25–36

    CAS  PubMed  Google Scholar 

  46. Kramlinger KG, Post RM . The addition of lithium to carbamazepine Arch Gen Psychiatry 1989 46: 794–800

    Article  CAS  PubMed  Google Scholar 

  47. Placidi GF, Lenzi A, Lazzerini F . The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-bind 3-year trial in 83 patients J Clin Psychiatry 1986 47: 490–494

    CAS  PubMed  Google Scholar 

  48. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic depressive illness Psychopharmacology 1981 73: 95–96

    Article  CAS  PubMed  Google Scholar 

  49. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study J Affect Disord 1997 43: 151–161

    Article  CAS  PubMed  Google Scholar 

  50. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM . Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder J Clin Psychiatry 1997 58: 470–478

    Article  CAS  PubMed  Google Scholar 

  51. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR et al. Clozapine in the treatment of psychotic mooddisorders, schizoaffective disorder, and schizophrenia J Clin Psychiatry 1991 52: 411–414

    CAS  PubMed  Google Scholar 

  52. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA et al. Clozapine for treatment-refractory mania Am J Psychiatry 1996 153: 759–764

    Article  CAS  PubMed  Google Scholar 

  53. Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA et al. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics J Affect Disord 1998 48: 91–104

    Article  CAS  PubMed  Google Scholar 

  54. Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up J Clin Psychiatry 1994 55: 295–300

    CAS  PubMed  Google Scholar 

  55. Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E . Response to clozapine in acute mania is more rapid than that of chlorpromazine Int Clin Psychopharmacol 1997 12: 109–112

    Article  CAS  PubMed  Google Scholar 

  56. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ . Clinical outcome in randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and history of mania Am J Psychiatry 1999 156: 1164–1169

    CAS  PubMed  Google Scholar 

  57. Ghaemi SN, Sach GS . Long-term risperidone treatment in bipolar disorder: 6-month follow-up Int Clin Psychopharmacol 1997 12: 333–338

    Article  CAS  PubMed  Google Scholar 

  58. Hillert A, Maier W, Wetzel H, Benkert O . Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome—a functional approach Pharmacopsychiatry 1992 25: 213–217

    Article  CAS  PubMed  Google Scholar 

  59. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders J Clin Psychiatry 1995 56: 466–470

    PubMed  Google Scholar 

  60. Segal J, Berk M, Brook S . Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial Clin Neuropharmacol 1998 21: 176–180

    CAS  PubMed  Google Scholar 

  61. Sachs GS Risperidone Bipolar Study Group. Safety and efficacy of risperidone vs placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder. Presented at the 38th Annual Meeting of the ACNP, Acapulco, Mexico, December 1999

  62. Keck PE Jr, Ice K . A three-week double-blind, randomized trial of ziprasidone in placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder. Presented at the 38th Annual Meeting of the ACNP, Acapulco, Mexico, December 1999

  63. Keck PE Jr, Reeves KR, Harrigan EP . A double-bind, placebo-controlled study of ziprasidone in the acute treatment of patients with schizoaffective disorder J Clin Psychopharmacol 2001 21: 27–35

    Article  CAS  PubMed  Google Scholar 

  64. Ghaemi SN, Katzow JJ . The use of quetiapine for treatment-resistant bipolar disorder: a case series Ann Clin Psychiatry 1999 11: 137–140

    Article  CAS  PubMed  Google Scholar 

  65. Keck PE Jr . New antiepileptics and atypical antipsychotics in the treatment of bipolar disorder. Clinical issues in bipolar disorder: Data from the Stanley Foundation Bipolar Network Scientific Program of the American Psychiatric Association Annual Meeting, New Orleans, LA 2001

    Google Scholar 

  66. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G . Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy Bipolar Disord 2000 2: 249–255

    Article  CAS  PubMed  Google Scholar 

  67. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders J Clin Psychopharmacol 2000 20: 607–614

    Article  CAS  PubMed  Google Scholar 

  68. Anand A, Oren DA, Berman RM et al. Lamotrigine treatment of lithium failure outpatient mania: a double-blind, placebo-controlled trial. Abstracts of the 3rd International Conference on Bipolar Disorder, Pittsburgh, PA. Munksgaard: Copenhagen, Denmark 1999 p 23

  69. Ichim L, Berk M, Brook S . Lamotrigine compared with lithium in mania: a double-blind, randomized controlled trial Ann Clin Psychiatry 2000 12: 5–10

    Article  CAS  PubMed  Google Scholar 

  70. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD . A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression J Clin Psychiatry 1999 60: 79–88

    Article  CAS  PubMed  Google Scholar 

  71. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder J Clin Psychiatry 2000 61: 841–850

    Article  CAS  PubMed  Google Scholar 

  72. Muller AA, Stoll K-D . Carbamazepine and oxcarbazepine in the treatment of manic syndromes: studies in Germany In: Emrich HM, Okuma T, Muller AA (eds) Anticonvulsants in Affective Disorders Excerpta Medica: Amsterdam, The Netherlands 1984 pp 134–147

    Google Scholar 

  73. Emrich HM . Studies with oxcarbazepine (Trileptalin acute®) mania Int Clin Psychopharmacol 1990 5 (Suppl): 83–88

    Google Scholar 

  74. Cabrera JF, Muhlbauer HD, Schley J et al. Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders: preliminary results Pharmacopsychiatry 1986 19: 282–283

    Article  Google Scholar 

  75. Wildgrube C . Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders Int Clin Psychopharmacol 1990 5 (Suppl): 89–94

    Google Scholar 

  76. Calabrese JR . Topiramate versus placebo in the treatment of acute mania. Presented at the European College of Neuropsychopharmacology Meeting. London, UK: September 2000

  77. Blackshear MA, Sanders-Bush E . Serotonin receptor sensitivity after acute and chronic treatment with mianserin J Pharmacol Exp Ther 1982 221: 303–308

    CAS  PubMed  Google Scholar 

  78. Keck PE Jr, McElroy SL, Strakowski SM, West SA . Pharmacologic treatment of schizoaffective disorder Psychopharmacology 1994 114: 529–538

    Article  PubMed  Google Scholar 

  79. Vaidya VA, Duman RS . Role of 5HT2 receptors in down-regulation of BDNF by stress Neurosci Letts 1999 287: 1–4

    Article  Google Scholar 

  80. Anand A, Charney D . Abnormalities in catecholamines and pathophysiology of bipolar disorder In: Soares JC, Gershon S (eds) Bipolar Disorders. Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 59–94

    Google Scholar 

  81. Janowsky DS, Overstreet DH . Cholinergic dysfunction in mood disorders In: Soares JC, Gershon S (eds) Bipolar Disorders, Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 95–120

    Google Scholar 

  82. Oquendo MA, Mann JJ . Serotonergic dysfunction in mood disorders In: Soares JC, Gershon S (eds) Bipolar Disorders. Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 121–142

    Google Scholar 

  83. Massat I, Souery D, Mendelewicz J et al. The GABAergic hypothesis of mood disorders In: Soares JC, Gershon S (eds) Bipolar Disorders. Basic Mechanisms and Therapeutic Implications Marcel Dekker: New York 2000 pp 143–166

    Google Scholar 

  84. Hokin LE, Dixon JF, Los GV . Acute inhibition but chronic upregulation and stabilization of glutamate uptake in synaptosomes by lithium In: Manji HK, Bowden CL, Belmaker RH (eds) Bipolar Medications: Mechanisms of Action American Psychiatric Press: Washington, DC 2000 pp 65–86

    Google Scholar 

  85. Post RM, Weiss SRB, Clark M et al. Lithium, carbamazepine, and valproate in affective illness: biochemical and neurobiological mechanisms In: Manji HK, Bowden CL, Belmaker RH (eds) Bipolar Medications: Mechanisms of Action American Psychiatric Press: Washington, DC 2000 pp 219–248

    Google Scholar 

  86. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P . BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization Nature 2001 411: 86–89

    Article  CAS  PubMed  Google Scholar 

  87. Richtand N, Woods SC, Berger SP et al. D3 dopamine receptor, behavioral sensitization, psychosis Neurosci Biobehav Rev 2001 25: 427–443

    Article  CAS  PubMed  Google Scholar 

  88. Chen G, Huang LD, Zeng WZ, K Manji H . Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability Int J Neuropsychopharmacol 2001 4: 47–64

    Article  CAS  PubMed  Google Scholar 

  89. Tohen M, Jacobs TG, Meyers TM et al. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. New Research Program and Abstracts of the American Psychiatric Association Annual Meeting, Chicago, IL 2000 p 160

  90. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder J Clin Psychiatry 1997 58: 95–99

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Biological Psychiatry Program, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    P E Keck Jr & S L McElroy

  2. Department of Psychiatry, Cincinnati Veteran Affairs Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    N Richtand

  3. Eli Lilly and Company, Indianapolis, IN, USA

    M Tohen

  4. Consolidated Department of Psychiatry, Harvard Medical School, Boston, MA, USA

    M Tohen

Authors
  1. P E Keck Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S L McElroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Richtand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Tohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P E Keck Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keck Jr, P., McElroy, S., Richtand, N. et al. What makes a drug a primary mood stabilizer?. Mol Psychiatry 7 (Suppl 1), S8–S14 (2002). https://doi.org/10.1038/sj.mp.4001013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4001013

Keywords

Search

Advanced search

Quick links